EAST SETAUKET, N.Y., Aug. 12 /PRNewswire-FirstCall/ -- Lixte Biotechnology Holdings, Inc. (OTC Bulletin Board: LIXT) announced today that it had filed a patent application for the use of compounds the company is developing for treatment of brain tumors as potential treatments for neurodegenerative diseases including Alzheimer's and Parkinson's Disease.
Dr. John S. Kovach, President and CEO of Lixte, said, "Lixte has developed a series of novel compounds that inhibit the growth of common brain cancers of adults and children in mouse models. We have now found that some variants of these compounds have effects on brain cells that are believed to be potentially useful for the treatment of common neurodegenerative brain diseases. Since Lixte is focused primarily on developing anti-cancer drugs, we are exploring partnerships with companies that have expertise and research programs in the treatment of Alzheimer's Disease."
About Lixte Biotechnology Holdings, Inc.:
Lixte Biotechnology Holdings, Inc. is a cancer therapeutics and diagnostics company. Founded as a biomarker-diagnostics company in 2005, Lixte develops new chemotherapy drugs targeting molecular abnormalities of common human cancers.
This announcement contains certain forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933, and Section 21E
of the Securities Exchange Act of 1934. For example, statements regarding
the Company's financial position, business strategy and other plans and
objectives for future operations, and assumptions and predictions about
future product demand, supply, manufacturing, costs, marketing and pricing
factors are all forward-looking statements. These statements are generally
accompanied by words such as "intend," anticipate," "believe," "estimate,"
"potential(ly)," "continue," "forecast," "predict," "plan," "may," "will,"
"could," "would," "should," "expect" or the negative of such terms or other
comparable terminology. The Company believes that the assumptions and
expectations reflected in such forward-looking statements are reasonable,
based on information available to it on the date hereof, but the Company
cannot provide assurances that these assumptions and expectations will
prove to have been correct or that the Company will take any action that
the Company may presently be planning. However, these forward-looking
statements are inherently subject to known and unknown risks and
uncertainties. Actual results or experience may differ materially from
those expected or anticipated in the forward-looking statements. Factors
that could cause or contribute to such differences include, but are not
limited to, regulatory policies, available cash, research results,
competition from other similar businesses, and market and general economic
factors. This discussion should be read in conjunction with the condensed
consolidated financial statements and notes thereto included on Form 10-QSB
for the quarter ending June 30, 2008.
Please see our Website: http://www.Lixte.com
For Investor Information, please contact:
Mirador Consulting, Inc. 561-989-3600
|SOURCE Lixte Biotechnology Holdings, Inc.|
Copyright©2008 PR Newswire.
All rights reserved